Ferring Pharmaceuticals is set to acquire Gameto in a transaction valued at up to $1.38 billion, according to details provided with the announcement. Gameto focuses on cell engineering approaches for fertility. The deal signals continued consolidation in reproductive health and adds another asset pathway as companies try to translate platform biology into scalable clinical programs. Integration and pipeline continuity will be key watchpoints for investors and trial planners.